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Abstract: A signiﬁ  cant proportion of patients with chronic hepatitis C virus (HCV) infection 
who undergo antiviral therapy have persistent or recurrent viremia and fail to achieve a sustained 
virologic response (SVR). Factors associated with treatment failure include HCV genotype 1 
infection, high serum HCV RNA levels, and advanced ﬁ  brosis. Consensus interferon (CIFN) is a 
synthetic type I interferon derived from a consensus sequence of the most common amino acids 
found in naturally occurring alpha interferon subtypes. Several prospective clinical studies have 
demonstrated that CIFN may be a treatment option in patients who have failed prior interferon-
based therapy, including those who have failed combination therapy with standard interferon 
or peginterferon plus ribavirin. Daily CIFN in combination with ribavirin may be an effective 
regimen in this setting; however, optimal dose and treatment duration of CIFN therapy have 
not been well established. Patients who achieve viral suppression during prior interferon-based 
therapy and those who do not have advanced ﬁ  brosis have a greater likelihood of achieving a 
SVR with CIFN retreatment. Individualized therapy targeting speciﬁ  c patient groups will be an 
important consideration in the successful management of prior treatment failures. Additional 
prospective studies are required in order to identify optimal treatment strategies for the use of 
CIFN in these patients.
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Introduction
Hepatitis C virus (HCV) infection is the most common cause of newly diagnosed 
chronic liver disease in the United States, accounting for up to two-thirds of all cases.1 
Approximately 20% of chronic HCV-infected individuals may subsequently develop 
cirrhosis,2 resulting in an increased risk of progressive liver failure and hepatocellular 
carcinoma (HCC). Antiviral therapy is an important consideration in the management of 
patients with chronic HCV infection, as a sustained virologic response (SVR) to therapy 
may halt ﬁ  brosis progression, decrease the risk of HCC, and improve survival.3–5
Treatment regimens for chronic hepatitis C have evolved over the last 12 years, 
resulting in improved SVR rates. Despite these advances, the current gold standard 
therapy with peginterferon alfa-2a or alfa-2b (PEG IFN) and ribavirin (RBV) is suc-
cessful in only one-half of treated patients.6,7 Various clinical and virologic factors 
are well established as predictors of a reduced response to interferon-based therapy, 
including genotype 1, high baseline serum HCV RNA level, obesity, African Ameri-
can ethnicity, older age, and presence of advanced ﬁ  brosis or cirrhosis.6–9 Therefore, a 
signiﬁ  cant proportion of treated patients, particularly those infected with HCV geno-
type 1, will have persistent or recurrent viremia in spite of therapy and are potential 
candidates for retreatment.
Consensus interferon (CIFN) is a synthetic recombinant type I interferon protein 
derived from a consensus sequence of the most common amino acids found in naturally 
occurring alpha interferon subtypes. Although CIFN is not considered a ﬁ  rst-line agent 
in the treatment of naïve patients with chronic hepatitis C, it may have a potential role Biologics: Targets & Therapy 2009:3 142
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in the management of patients who previously failed prior 
interferon-based therapy.
Standard of care 
with interferon-based therapy
Since the initial studies utilizing standard interferon alpha 
(IFN) monotherapy in the treatment of chronic HCV 
infection,10 interferon-based therapy has proven to be 
effective in suppressing HCV RNA to undetectable levels on 
treatment and achieving persistent undetectability 6 months 
after completion of therapy, ie, an SVR. The addition of 
ribavirin was subsequently demonstrated in prospective 
clinical trials to result in improved outcomes with higher SVR 
rates compared to that achieved with IFN monotherapy.11,12 
A further improvement was the replacement of standard IFN 
with PEG IFN, which, in combination with RBV,6,7 is the 
most effective antiviral regimen in naïve patients and the 
current standard of care.13 PEG IFN plus RBV is associated 
with an SVR of up to 52% in genotype 1 patients following 
a 48-week course of therapy and 81% in genotype 2 and 
3 patients following a 24-week course of therapy.6–8 An SVR 
is a durable response and indicates eradication of HCV, with 
documented long-term undetectable serum HCV RNA in up 
to 18 years of follow-up.5
Although these results are gratifying, a significant 
proportion of patients, particularly those infected with HCV 
genotype 1, fail antiviral therapy. Treatment failure is deﬁ  ned 
as the presence of detectable serum HCV RNA 6 months 
following the completion of therapy, although failure may 
be recognized earlier in the course of therapy. Patients under-
going antiviral therapy may develop breakthrough viremia 
following a period of undetectable HCV RNA during a 
course of therapy, relapse of viremia following completion 
of therapy, or may be considered “null” responders with 
persistent viremia throughout their course of treatment. 
Due to a negative predictive value approaching 100% in 
patients who fail to achieve an early virologic response 
(EVR, deﬁ  ned by at least a 2-log10 decrease in HCV RNA by 
week 12), these patients are considered nonresponders and 
therapy is discontinued at this time point.7,14 Additionally, 
any patients with detectable HCV RNA after 24 weeks of 
therapy will not achieve an SVR, and thus are also classiﬁ  ed 
as nonresponders.
Peginterferon in the retreatment 
of chronic HCV
Peginterferon in combination with RBV may be considered 
as a treatment option in patients who failed prior IFN therapy. 
Several prospective studies have found that nonresponders 
to prior courses of standard IFN monotherapy and relapsers 
to standard IFN with or without RBV may derive the most 
beneﬁ  t from retreatment with PEG IFN and RBV.15–22 Prior 
nonresponders to standard IFN monotherapy achieve SVR 
rates ranging from 21% to 28% with PEG IFN and RBV 
treatment,15–19 while relapsers to combination standard IFN 
and RBV have been reported to achieve SVR in 38% to 58% 
of cases with PEG IFN and RBV.16–21 In contrast, combination 
therapy null responders to IFN and RBV tend to demonstrate 
relatively poor responses to retreatment with PEG IFN and 
RBV, with an SVR ranging from 8% to 15%,15–17,21 but up to 
20% in patients with lower baseline HCV RNA levels.18,19,22 
Based on these studies, patients with low baseline HCV RNA 
levels or mild to moderate ﬁ  brosis appear to have a greater 
potential for a SVR.15,16,18,21,22 In patients who are PEG IFN 
nonresponders, there is virtually no role for retreatment with 
repeated courses of PEG IFN, as these patients have demon-
strated a resistance to this form of therapy and would likely 
have a negligible potential for achieving SVR. Altogether, 
given these relatively low retreatment response rates, there 
is a need for alternative therapies in previous nonresponders 
to IFN-based therapy. Thus, CIFN may be a treatment option 
in selected patients with chronic hepatitis C who have failed 
previous IFN-based therapy.
Consensus interferon
Type 1 interferons, notably IFN-α and IFN-β, play a critical 
role in the host antiviral response to HCV through inhibitory 
effects on viral production and activation of cellular immunity 
and clearance of infected cells.23 Activation of transcription 
factors within infected cells leads to a transcriptional response 
promoting the secretion of type 1 IFNs and subsequent 
activation of the Janus kinase-signal transducer and activator 
of transcription (JAK-STAT) signal transduction pathway. 
This process results in transcriptional activity within infected 
cells that promotes inhibition of HCV replication through 
the disruption of viral RNA translation and RNA synthesis. 
These events induce an antiviral state which limits cell-to-cell 
virus spread and primes immune effector cells involved in 
host adaptive immunity.23
In addition to having an important role in host endogenous 
antiviral responses to HCV, IFNs, particularly IFN-α, have 
demonstrated clinical efﬁ  cacy in the treatment of chronic 
HCV infection. In contrast to IFN-β which is derived from a 
single gene encoding for a speciﬁ  c protein, IFN-α is a family 
of proteins with over a dozen subtypes differing in their 
respective amino acid sequences.24 CIFN is a synthetic protein Biologics: Targets & Therapy 2009:3 143
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engineered by the creation of a consensus sequence involving 
the most common amino acids found in naturally occurring 
alpha interferon subtypes. In vitro studies have suggested 
that CIFN may have more enhanced biologic activity and 
increased antiviral efﬁ  cacy compared with naturally occurring 
IFN-α subtypes such as IFN alfa-2a and IFN alfa-2b.25
Various dosing regimens of CIFN have been studied, 
although the optimal dose in naïve patients or in the setting of 
retreatment has not been well established. The recommended 
dosing based on initial phase III clinical trials is 9 μg 3 times 
weekly in treatment-naïve patients and 15 μg 3 times weekly 
in nonresponders.26 One prospective randomized trial found 
no improvement in SVR with higher doses CIFN at 18 μg 
versus 9 μg when given 3 times weekly in combination with 
RBV.27 Additionally, high doses of CIFN may be associ-
ated with a greater need for dose reductions due to adverse 
events.27 The rate of SVR associated with CIFN therapy 
could potentially be further improved with daily dosing, 
as this may achieve optimal viral suppression and similar 
kinetics to long-acting PEG IFN, resulting in a greater viro-
logic response.28 As a result, recent studies have explored 
the role of daily CIFN therapy, which we will discuss in 
greater detail below. Table 1 summarizes the various clinical 
trials that have evaluated CIFN in the retreatment of prior 
therapy failures in patients with chronic HCV infection, 
while Figures 1 and 2 depict reported rates of SVR in prior 
treatment relapsers and nonresponders, respectively.
Consensus interferon in naïve patients 
with chronic hepatitis C
Initial clinical trials of CIFN monotherapy as a treatment 
for chronic hepatitis C in naïve patients at a dose of 9 μg 
demonstrated greater reduction in serum HCV RNA and 
comparable long-term efﬁ  cacy compared with standard IFN 
alfa-2b when given 3 times weekly.29 Subsequent prospective 
studies suggested that CIFN may have a signiﬁ  cant advantage 
over standard IFN, particularly for difﬁ  cult-to-treat patients 
with higher baseline serum HCV RNA levels and those 
infected with HCV genotype 1.30,31 The development of PEG 
IFN alfa-2a and alfa-2b has resulted in the ability to achieve 
a substantially higher rate of SVR in naïve patients6,7 and at 
this time, a pegylated formulation of CIFN is not available. 
Although one recent study revealed that CIFN 3 times weekly 
in combination with weight-based RBV may be as effective 
as combination PEG IFN alfa-2b and weight-based RBV in 
the treatment of HCV genotype 1 patients, comparative data 
are limited.32 Therefore CIFN is not considered the standard 
of care for naïve patients with chronic HCV infection.
Consensus interferon in the retreatment 
of chronic hepatitis C
Consensus interferon monotherapy
As initial attempts at IFN-based therapy for the treatment 
of chronic hepatitis C were associated with high rates 
of nonresponse and relapse, CIFN was introduced as an 
alternative therapy for patients who failed prior courses of 
standard IFN alfa-2a or alfa-2b in the hopes of achieving 
an SVR with retreatment. An early study was notable for 
SVR rates of 13% and 58% for nonresponders and relaps-
ers, respectively, following a course of 48 weeks of CIFN 
monotherapy at 15 μg 3 times weekly in those who had 
previously received only 24 weeks of either IFN alfa-2b or 
lower-dose CIFN (3 μg 3 times weekly).33 Further analysis of 
this study suggested that nonresponder patients who managed 
to achieve viral clearance during prior therapy followed by 
virologic breakthrough had a greater likelihood of SVR with 
CIFN retreatment.34 Similar SVR rates have been reported in 
IFN monotherapy relapsers with daily dosing of CIFN over 
a 24-week course, with a signiﬁ  cantly greater frequency of 
SVR compared with combination IFN and RBV.35 CIFN 
monotherapy has also been studied in genotype 1 patients 
who failed prior therapy with combination standard IFN and 
RBV. SVR rates of up to 33% and 42% have been reported 
for combination nonresponders and relapsers treated with 
CIFN monotherapy, respectively, with a greater likelihood of 
SVR seen in patients with low baseline HCV RNA levels and 
minimal ﬁ  brosis.36 However, lower response rates have also 
been reported in this population37 and CIFN monotherapy 
may not be sufﬁ  cient to achieve SVR in patients who were 
null responders to combination therapy with RBV.
Consensus interferon in combination with ribavirin
As in the case of IFN alfa-2a and alfa-2b therapy, many 
prospective studies have reported a greater likelihood of 
achieving SVR in the retreatment of prior therapy failures 
when combining CIFN with RBV as opposed to CIFN 
monotherapy. Consequently, in order to provide optimal viral 
suppression, more recent studies have evaluated the role of 
CIFN in combination with RBV as retreatment for chronic 
hepatitis C. Based on the results from trials involving CIFN 
as monotherapy, various dosing regimens have been used, 
initially with CIFN administered 3 times weekly or daily 
dosing. Several prospective randomized trials have also 
evaluated the use of high-dose induction therapy with CIFN 
early during a course of retreatment;38–40 however, it appears 
that this strategy might not have a signiﬁ  cant impact on SVR, 
as noted in treatment-naïve patients who received CIFN.41Biologics: Targets & Therapy 2009:3 144
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Interferon monotherapy failure
Patients who were null responders or relapsed following 
a course of standard IFN monotherapy might be ideal 
candidates for retreatment, as they might beneﬁ  t from the 
addition of RBV to IFN-based therapy. Two prospective 
European trials reported a signiﬁ  cant improvement in SVR 
rates in standard IFN monotherapy nonresponders when 
retreated with CIFN and RBV combination therapy.39,40 Both 
of these studies included at least 24 weeks of daily CIFN, 
and the SVR rate reached 39% with daily CIFN treatment 
over a 48-week course.40 Another European study evalu-
ated CIFN 3 times weekly plus RBV in previous relapsers 
to standard IFN monotherapy.42 Of note, this trial reported 
discontinuation due to adverse events in over one quarter 
of patients enrolled, which may have resulted in a lower 
SVR than expected.
Combination interferon and ribavirin failure
CIFN and RBV therapy for prior nonresponders to combination 
standard IFN plus RBV appears to result in SVR rates that are 
comparable to, and in some cases exceed, those that have been 
reported with PEG IFN plus RBV retreatment regimens.38–40,43 
The most impressive response rates have emerged from two 
studies that reported an SVR ranging from 36% to 45%.38,43 
Although one study had a relatively small sample size, the 
study with the highest reported SVR by Kaiser and colleagues 
enrolled 121 combination IFN/RBV nonresponders.37 These 
prospective studies included a majority of patients with 
genotype 1 infection and up to approximately one-third with 
advanced ﬁ  brosis on liver biopsy. Combination IFN plus 
RBV relapsers may potentially have an even greater virologic 
response to CIFN-based therapy, although this population 
has not been studied as extensively. One randomized clinical 
trial by Bocher and colleagues, which combined one-third 
IFN relapsers and two-thirds IFN/RBV relapsers, reported a 
rate of SVR up to 70% in a treatment arm that received daily 
CIFN at induction doses up to 27 μg subcutaneously per day 
with ongoing daily therapy for 24 weeks followed by dosing 
3 times weekly for the remainder of the 48-week course.39 
However, due to a relatively low number of patients, the 
results were not statistically different from a noninduction 
arm with a SVR of 38%. Taken together, the overall SVR of 
relapsers in this trial was 47%.
Combination peginterferon and ribavirin failure
The most challenging population of patients who might 
beneﬁ  t from retreatment is patients who have failed prior 
combination therapy with the current gold standard of PEG 
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IFN and RBV. In this population with limited options for 
retreatment, CIFN might have an important role in successful 
clearance of HCV infection. Particularly those who have 
relapsed to prior PEG IFN and RBV may derive the most 
beneﬁ  t from retreatment with CIFN. One retrospective study 
by Ghalib et al44 and one prospective study with an extended 
72-week course by Kaiser et al45 reported SVR rates of 47% 
and 69%, respectively, with daily CIFN plus RBV. Kaiser 
and colleagues also noted that daily CIFN plus RBV was 
superior to retreatment with combination PEG IFN and RBV 
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over a 72-week course in these patients. Prior nonresponders 
to PEG IFN and RBV are more challenging with retreatment 
and response rates may be signiﬁ  cantly inﬂ  uenced by liver 
histology. Although one prospective study reported SVR 
rates as high as 31% in nonresponders to PEG IFN and 
RBV who are retreated with daily CIFN plus RBV,38 another 
retrospective study revealed a much lower response rate 
of 10%.44 This difference in SVR may be explained by the 
number of patients with bridging ﬁ  brosis or cirrhosis on liver 
biopsy, which was reported to be 28% versus 63% for each 
of these studies, respectively. In addition, the largest prospec-
tive trial to date evaluating the efﬁ  cacy of daily CIFN and 
RBV in this population, known as the Daily-Dose Consensus 
Interferon and Ribavirin: Efﬁ  cacy of Combined Therapy 
(DIRECT) Trial, appears to show no major improvement in 
SVR overall, although this trial involved a difﬁ  cult-to-treat 
population characterized by a significant proportion of 
patients with advanced ﬁ  brosis.46
A novel approach utilizing CIFN therapy in nonre-
sponders to combination PEG IFN and RBV has been 
described by Leevy in which patients who fail to achieve 
an EVR at 12 weeks of therapy on PEG IFN/RBV are con-
verted to daily CIFN plus RBV with no wash-out period.47 
Although a retrospective design was used in the selection 
of patients for this study, it provides an alternative strategy 
that may improve rates of SVR in an otherwise challenging 
group of patients with predominantly genotype 1 infection, 
high HCV RNA levels, and one-third African-American 
ethnicity. Patients who would otherwise discontinue therapy 
at 12 weeks due to failure to achieve an EVR7,14 completed 
an additional 48-week course of antiviral therapy consisting 
of RBV plus CIFN 15 μg daily for 12 weeks followed by 
15 μg 3 times weekly for 36 weeks. This 72-week regimen 
was associated with an overall SVR of 37% in comparison 
with an SVR of approximately 11%, which has been reported 
in EVR-negative patients who complete 72 weeks of PEG 
IFN and RBV.48
The DIRECT trial
The DIRECT trial is a multicenter, open-label, phase III 
study evaluating the efﬁ  cacy of daily CIFN plus RBV in 
previous nonresponders to PEG IFN and RBV combination 
therapy.46 It is the largest prospective clinical trial involv-
ing the use of CIFN in this population to date. Although 
the DIRECT trial has yet to be published as a manuscript, 
the ﬁ  nal results have been presented in abstract form. All 
patients enrolled in the study were considered nonresponders 
with less than a 2-log10 decline in HCV RNA at 12 weeks 
during their previous course of PEG IFN plus RBV therapy 
or they had persistent viremia following at least 24 weeks of 
therapy. Patients were randomized to one of three treatment 
arms: CIFN 9 μg daily plus RBV for 48 weeks; CIFN 15 μg 
daily plus RBV for 48 weeks; or no treatment (Figure 3). 
Patients randomized to not receive treatment were eligible 
for a roll-over study at 24 weeks in which they could be 
randomized a second time to receive therapy as detailed in 
the treatment arms. Final data from 343 patients enrolled in 
the two treatment arms revealed overall SVR rates of 10% and 
5% in the 15 μg and 9 μg groups, respectively. Subanalyses 
found that cirrhotics and prior null responders, deﬁ  ned by 
PEG IFN + RBV
Nonresponders
Randomization
n = 515
CIFN 15 μg daily + RBV
n = 172 
No Treatment
n = 172
CIFN 9 μg daily + RBV
n = 74 
CIFN 15 μg daily + RBV
n = 70 
CIFN 9 μg daily + RBV
n = 171 
24 weeks
24 weeks
48 weeks
Figure 3 DIRECT trial protocol and randomization scheme.46
Abbreviations: CIFN, consensus interferon; DIRECT, Daily-Dose Consensus Interferon and Ribavirin: Efﬁ  cacy of Combined Therapy; PEG IFN, peginterferon; RBV, ribavirin.Biologics: Targets & Therapy 2009:3 148
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inability to achieve a 2-log10 decline in HCV RNA, had a 
signiﬁ  cantly lower SVR rate. Noncirrhotic patients in the 
15 μg treatment arm who demonstrated at least a 2-log10 
decline in HCV RNA during prior therapy had the highest 
subgroup SVR at 29%. The DIRECT trial was characterized 
by a predominantly difﬁ  cult-to-treat population, which may in 
part explain the lower overall SVR compared with other stud-
ies evaluating CIFN-based therapy in prior PEG IFN/RBV 
nonresponders. The majority of patients in the DIRECT trial 
were described as having high HCV RNA levels, 79% were 
considered null responders during previous treatment, 94% 
had genotype 1 infection, 59% had evidence of bridging ﬁ  bro-
sis or cirrhosis on liver biopsy, and approximately 20% were 
of African-American ethnicity. Despite these challenges, the 
DIRECT trial most importantly identiﬁ  ed potential subgroups 
of patients who have failed previous therapy and would 
beneﬁ  t most from retreatment.
Tolerability and adverse events
Interferon-based therapy is known to be associated with 
signiﬁ  cant side effects that may have an impact on tolerability, 
compliance, ability to maintain optimal dosing regimens, and 
ultimately response to therapy if dose reductions or discon-
tinuations are required. As CIFN has been shown to have 
potent antiviral effects and has been studied with frequent 
dosing intervals up to once daily, the incidence of adverse 
events may be an important consideration in the retreatment of 
prior treatment failures. The side effect proﬁ  le associated with 
CIFN is essentially the same as with other forms of IFN-based 
therapy.26 In addition, the incidence and frequency of adverse 
events during a course of combination CIFN and RBV therapy 
is similar to what has been reported in clinical trials of PEG 
IFN and RBV.6–8 The most common side effects that have been 
reported in clinical trials with CIFN include ﬂ  u-like symp-
toms, gastrointestinal symptoms, rash, and depression. The 
frequency of these adverse events as noted in Table 2 include 
trials that involve daily dosing of CIFN up to 15 μg per day 
and, in some cases induction doses up to 27 μg per day. Based 
on these reported adverse events, there is no clear evidence 
that daily dosing of CIFN might result in an increase in side 
effects or a signiﬁ  cant decline in tolerability as compared with 
weekly PEG IFN. The rates of discontinuation for adverse 
events and dose reductions in CIFN are also comparable to 
the rates reported with PEG IFN therapy.
Conclusion
Consensus interferon is a viable option in the retreatment of 
patients with chronic HCV who have failed prior IFN-based 
therapy and may have an important role for individuals who 
would otherwise be considered poor candidates for therapy 
based on a lower likelihood of achieving an SVR. Studies 
suggest that CIFN may have greater antiviral activity in vitro 
when compared to IFN-α and may have greater efﬁ  cacy in 
difﬁ  cult-to-treat populations, such as patients with high viral 
load and genotype 1 infection, and not have an increased 
incidence of adverse events compared with PEG IFN. 
Alternatively, CIFN requires more frequent dosing and 
potentially closer patient follow-up to ensure compliance. 
Many recent studies have utilized a daily dosing regimen 
of CIFN in order to provide more favorable kinetics and 
achieve maximal viral suppression during a course of therapy. 
Although the preferred dose of CIFN, duration of therapy, 
and timing of therapy in the setting of retreatment have not 
been well-established, daily weight-based RBV should be 
used in combination with CIFN in order to achieve optimal 
rates of SVR.
Several prospective clinical trials have identiﬁ  ed patient 
populations who might beneﬁ  t most from retreatment and 
have a greater potential for a successful course of therapy 
with CIFN. In light of these ﬁ  ndings, clinicians should 
target these groups when considering potential candidates 
for retreatment. Patients who may particularly beneﬁ  t from 
CIFN retreatment include prior nonresponders to standard 
IFN plus RBV as well as nonresponders and relapsers to 
prior PEG IFN plus RBV. These individuals otherwise 
have limited options as retreatment with conventional PEG 
IFN and RBV may be associated with low response rates. 
Table 2 Most common adverse events associated with consensus 
interferon reported in clinical trialsa
Adverse event Frequency (%)
Constitutional symptoms
 Flu-like  symptoms 43–98
 Nausea 21–36
 Rash 10–32
 Depression 21–26
 Diarrhea 22–25
Hematologic abnormalities
 Neutropenia 16–29
 Anemia 6–29
 Thrombocytopenia 4–18
Dose reduction and discontinuation
   Dose reduction of CIFN for adverse event 5–43
  Discontinuation for adverse event 7–33
aIncludes studies with consensus interferon at subcutaneous doses up to 15 μg daily 
for 48 weeks as well as induction doses up to 27 μg daily.26,33,35–40,42–47Biologics: Targets & Therapy 2009:3 149
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In addition, patients who achieved a signiﬁ  cant degree 
of viral suppression during prior IFN-based therapy and 
patients with early stages of ﬁ  brosis have a greater likelihood 
of achieving a SVR with CIFN retreatment. The ability to 
achieve signiﬁ  cant viral suppression during a previous course 
of IFN-based therapy has been shown to be a predictor of 
successful response in several studies involving CIFN,34,40,46,47 
and has also been described in retreatment regimens that 
include PEG IFN.15,16,18,21,22 Liver histology also appears to 
have a signiﬁ  cant impact on virologic response associated 
with CIFN therapy, as patients who have not developed 
advanced ﬁ  brosis are more likely to achieve SVR with 
retreatment.46
Interpretation of the various clinical studies involving use 
of CIFN for prior therapy failures in chronic HCV infection 
can be challenging due to wide variations in study design, 
dosing regimens, duration of therapy, and patient popula-
tions. These studies are limited by differences in dosing 
and frequency of CIFN, inclusion of induction doses of 
CIFN at times without the use of RBV, and heterogeneous 
populations based on prior response to therapy. In addition, 
comparative data between CIFN and conventional IFN-based 
regimens is limited.35,45 Overall, these factors challenge our 
ability to determine whether CIFN-based regimens may 
indeed be superior to PEG IFN and RBV in the retreatment 
of HCV-infected individuals who failed prior IFN-based 
therapy. Despite these limitations, it is clear that some 
patients with chronic HCV may beneﬁ  t from retreatment 
with CIFN. Individualized therapy targeting speciﬁ  c patient 
groups will be an important consideration in successful 
management of these patients. Additional prospective studies 
of CIFN are needed to identify optimal treatment strategies 
as well as establish which populations will beneﬁ  t most from 
retreatment.
Abbreviations
CIFN, consensus interferon; DIRECT, Daily-Dose 
Consensus Interferon and Ribavirin: Efﬁ  cacy of Combined 
Therapy; EVR, early virologic response; HCC, hepatocel-
lular carcinoma; HCV, hepatitis C virus; IFN, interferon; 
JAK-STAT, Janus kinase-signal transducer and activator 
of transcription; MU, million units; NR, nonresponders; 
PEG IFN, peginterferon; QD, daily; QOD, every other day; 
RBV, ribavirin; SC, subcutaneous; SVR, sustained virologic 
response; TIW, 3 times weekly.
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